Doximity (DOCS) Stock Forecast & Price Target

Doximity is well positioned to continue its strong growth in the medical professional market while also diversifying its revenue sources with its AI suite and telehealth solutions. Despite a slower start to CY26 due to regulatory uncertainty, the company maintains a strong market position and is expected to grow at double the overall pharma advertising market rate with over 50% adusted EBITDA margins. Although there is competition in the market and concerns about the regulatory environment, the recent sell-off presents a buying opportunity for this promising company with potential for continued growth and innovation.

Doximity is a financial analyst writing about the company and has a negative outlook on the stock. Their concerns are primarily driven by the slower growth in existing customer expansion, as well as the compression in tech multiples. While the company's traditional metrics remain strong and their AI tools continue to grow, uncertainty around the trajectory of topline growth and the impact of recent industry-wide policy changes on customer budgeting decisions create a level of uncertainty for future performance. Additionally, the potential for competitive pressures and the risk of demand normalization could also impact the company's growth prospects. Based on these factors, the analyst has lowered their price target to $55 and has a fundamental outlook on the stock at 15x their CY2027 EBITDA estimate.